Log in
Enquire now
‌

US Patent 11072626 Small molecule inhibitors of Galectin-3

Patent 11072626 was granted and assigned to Bristol-Myers Squibb on July, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Bristol-Myers Squibb
Bristol-Myers Squibb
Current Assignee
Bristol-Myers Squibb
Bristol-Myers Squibb
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11072626
Date of Patent
July 27, 2021
Patent Application Number
16754381
Date Filed
October 10, 2018
Patent Citations Received
‌
US Patent 11939349 Galactoside inhibitor of galectins
0
Patent Primary Examiner
‌
Layla D Berry
Patent abstract

The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11072626 Small molecule inhibitors of Galectin-3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.